© 2020 MJH Life Sciences and OncLive. All rights reserved.
© 2020 MJH Life Sciences™ and OncLive. All rights reserved.
June 25, 2020
Yelena Y. Janjigian, MD, discusses updated results from the phase 2 DESTINY-Gastric01 trial in previously treated patients with HER2-positive gastric cancer.
June 17, 2020
Yelena Y. Janjigian, MD, discusses the rationale behind the plasma and tumor-based biomarker analysis of pembrolizumab in combination with trastuzumab and chemotherapy in HER2-positive metastatic esophagogastric cancer.
April 21, 2020
Yelena Y. Janjigian, MD, discusses data examining surgery plus extensive intraoperative peritoneal lavage versus surgery alone in patients with gastric cancer.
April 14, 2020
Yelena Y. Janjigian, MD, discusses results from the phase III JAVELIN Gastric 100 study evaluating avelumab in gastric or gastroesophageal cancer.